Skip Navigation

About Emma

Emma is a corporate lawyer advising domestic and international clients on a range of business matters, including financings, mergers and acquisitions, go-public events, complex shareholder negotiations, corporate governance, commercial transactions, joint ventures and partnerships.

Emma's practice covers a broad range of sectors and industries, including life sciences, health care, SaaS, AI and quantum computing, clean tech, and natural resources. A large part of Emma’s practice focuses on supporting innovative growth companies and particularly in the life science industry. She helps create negotiated solutions among stakeholders, including founder exits, government contracts and complex shareholder agreements.

Select Experience

Mergers, Acquisitions and Financings

  • Alpha-9 Oncology in connection with its US$175-million Series C preferred share financing

  • Orpyx Medical in connection with its US$20-million financing by Perceptive Advisors

  • Mediphage in connection with its seed round financing

  • Convergint in connection with its acquisition of Panavidéo

  • Disruption Ventures in connection with the C$1.5-million seed financing of Ginger Desk

  • HTEC in connection with its raise of C$337-million from the Canada Infrastructure Bank

  • Mediphage Bioceuticals in connection with its seed round financing

  • Conuma in connection with its purchase of the Quintette coal mine assets from Teck Resources for C$120-million

  • enGene in connection with its public transaction through a merger with a SPAC, Forbion European Acquisition Corporation, in a deal with US$138-million in gross proceeds

  • Abdera in connection with its US$110-million Series B financing

  • Tasktop Technologies Incorporated on its C$100-million in new financing from Sumeru Equity Partners

  • Alpha-9 Theranostics in connection with its US$75-million Series B financing

  • Incisive Genetics in connection with its C$12-million seed financing

  • Notch Therapeutics in connection with its US$85-million Series A financing

  • Later.com on its acquisition by Mavrck, in a deal funded by Summit Partners

  • adMare BioInnovations in connection with the C$8-million seed financing of Abdera Therapeutics

  • Hutton Family Holdings Ltd. in its acquisition of the assets of Fairview Cellars Winery

  • Alpha-9 Theranostics in connection with its US$11-million Series A financing

  • AbCellera Biologics in connection with its US$555.5-million initial public offering of common shares on NASDAQ

  • Brewster Travel Canada Inc. (an affiliate of Viad Corp.) on its acquisition of a majority equity interest in Mountain Park Lodges

  • D-Wave Systems Inc. in its public transaction through a merger with a SPAC, DPCM Capital, Inc., in a deal with an implied value of US$1.2-billion

  • Beijing BDStar Navigation Co., Ltd. on its acquisition of Canadian mobile positioning technology company Rx Networks Inc. with a total deal value of approximately C$31-million

  • Trilogy International Partners on its US$875-million business combination with Allignvest Acquisition Corporation, a special purpose acquisition corporation (SPAC)

  • Cognizant on their acquisition of Idea Couture, a privately held firm that offers digital innovation, strategy, design and technology services

  • Dominion Lending Centres Group in the sale of a 60% interest to Founders Advantage Capital Corp. for C$78-million

  • Foley's Candies in its sale to Yellow Point Equity Partners

  • Concert Infrastructure, Bird Construction and Bird Capital in their successful bid to construct, finance and maintain nine public-private partnership schools in Saskatchewan

Corporate Governance and Complex Commercial Transactions

  • Centre for Drug Research and Development in connection with its business combination with NEOMED Institute to create adMare BioInnovations

  • Acting for joint venture partners in forming various forms of joint ventures in the natural resource and manufacturing sectors

  • Representing companies and shareholders in complex governance matters, including the negotiation and renegotiation of complex multi-party shareholder agreements

  • Negotiating and drafting all manner of commercial and operational contracts specific to the retail, technology, agricultural and natural resource sectors

Competition and Foreign Investment

  • GlaxoSmithKline in connection with the Canadian antitrust aspects of its consumer healthcare, vaccines and oncology transactions with Novartis AG

  • Marine Harvest ASA on its acquisition of a significant minority interest in Grieg Seafood ASA

Awards & Recognition

Emma is recognized by the following publications:

  • The Best Lawyers in Canada 2025 (Corporate Law)

  • Thomson Reuters Stand-out Lawyers 2024 – Independently Rated Lawyers (As nominated by senior in-house counsel)

  • Best Lawyers: Ones to Watch in Canada – 2022–2023 (Corporate Law)

Publications
  • Co-author : British Columbia Business Corporations Act & Commentary
    LexisNexis Canada, 2024 Edition, 2024.
  • Co-author : British Columbia Business Corporations Act & Commentary
    LexisNexis Canada, 2023 Edition, 2023.
Education

Admitted to the British Columbia Bar – 2015
Admitted to the Ontario Bar – 2013
JD, University of Toronto – 2012
BA (Recipient of the Brian Coghlan Memorial Prize in Economics), McGill University – 2009

More insights

Save Profile

Select sections to customize your PDF

Cancel